<DOC>
	<DOCNO>NCT02457351</DOCNO>
	<brief_summary>To evaluate effect itraconazole , strong CYP3A4 inhibitor , pharmacokinetics roniciclib cancer patient . To assess safety tolerability roniciclib dose administer without itraconazole cancer patient</brief_summary>
	<brief_title>Roniciclib ( BAY 1000394 ) Drug-Drug Interaction ( DDI ) Study</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Male female patient â‰¥ 18 year age histological cytological confirm advanced solid tumor refractory , able tolerate standard therapy , standard therapy available , subject must actively refuse treatment would regard standard , / judgment investigator , experimental treatment clinically ethically acceptable . Adequate liver , renal bonemarrow function assess laboratory value . ECOG Performance Status 0 2 life expectancy least 12 week . Subject history hypertension stable antihypertensive treatment 7 day prior first dose study drug . Medical surgical history : Previous deep vein thrombosis ( within last 6 month ) , arterial thrombotic event ( include stroke ) , pulmonary embolism . History cardiac disease : congestive heart failure , angina ( within past 6 month prior study entry ) , myocardial infarction , cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) . Uncontrolled hypertension ( systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg despite optimal medical management ) Moderate severe hepatic impairment , i.e . ChildPugh class B C. History human immunodeficiency virus ( HIV ) infection chronic hepatitis B C Active clinically serious infection Common Terminology Criteria Adverse Events ( CTCAE , v. 4.03 ) &gt; Grade 2 . Symptomatic metastatic brain meningeal tumor unless subject &gt; 3 month definitive therapy , evidence tumor growth image study within 4 week prior study entry , clinically stable respect tumor time study entry . Seizure disorder require therapy ( steroids antiepileptic ) . History organ allograft . Use strong inhibitor and/or inducer CYP3A4 14 day study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>pan-CDK inhibitor</keyword>
	<keyword>Drug-drug Interaction</keyword>
</DOC>